Specificity of the anti-glycolytic activity of 3-bromopyruvate confirmed by FDG uptake in a rat model of breast cancer.
作者信息
Buijs Manon, Vossen Josephina A, Geschwind Jean-Francois H, Ishimori Takayoshi, Engles James M, Acha-Ngwodo Obele, Wahl Richard L, Vali Mustafa
机构信息
Russell H. Morgan Department of Radiology, and Radiological Sciences, Division of Vascular and Interventional Radiology, 600 North Wolfe Street, Blalock 545, Baltimore, MD 21287, USA.
出版信息
Invest New Drugs. 2009 Apr;27(2):120-3. doi: 10.1007/s10637-008-9145-0. Epub 2008 Jun 14.
PURPOSE
To evaluate the anti-glycolytic effects of 3-BrPA on rats bearing RMT mammary tumors, by determining FDG uptake after intravenous administration of the therapeutic dose.
MATERIALS AND METHODS
Sixteen rats bearing RMT tumors were treated either with 15 mM 3-BrPA in 2.5 ml of PBS or with 2.5 ml of PBS. After treatment, all rats received FDG and were sacrificed 1 h later.
RESULTS
3-BrPA treatment significantly decreased FDG uptake in tumors by 77% (p = 0.002). FDG uptake did not significantly decrease in normal tissues after treatment.
CONCLUSION
Our study showed that 3-BrPA exhibits a strong anti-glycolytic effect on RMT cells implanted in rats.
Zotero 插件